Soligenix (Soligenix) Days Sales Outstanding : 0.00 (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

What is Soligenix Days Sales Outstanding?

Soligenix's average Accounts Receivable for the three months ended in Dec. 2023 was $0.07 Mil. Soligenix's Revenue for the three months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for Soligenix's Days Sales Outstanding or its related term are showing as below:

During the past 13 years, Soligenix's highest Days Sales Outstanding was 1896.89. The lowest was 42.16. And the median was 106.77.

SNGX's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 71.92
* Ranked among companies with meaningful Days Sales Outstanding only.

Soligenix's Days Sales Outstanding declined from Dec. 2022 (56.12) to Dec. 2023 (0.00).

Soligenix Days Sales Outstanding Historical Data

The historical data trend for Soligenix's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soligenix Days Sales Outstanding Chart

Soligenix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

126.04

115.59

1,896.89

185.42

Soligenix Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															56.12	-	-	-	-

Competitive Comparison of Soligenix's Days Sales Outstanding

For the Biotechnology subindustry, Soligenix's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Soligenix's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Soligenix's Days Sales Outstanding falls into.

Soligenix Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Soligenix's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.115	+	0)	/	1 )	/	0	*	365
=	0.115					/	0	*	365
=	N/A

Soligenix's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.066	+	0)	/	1 )	/	0	*	365 / 4
=	0.066					/	0	*	365 / 4
=	N/A

Soligenix (NAS:SNGX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Soligenix Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Soligenix's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Soligenix (Soligenix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (NAS:SNGX) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540

Website

https://www.soligenix.com

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Executives

Timothy R. Cote	director	3529 TILDEN STREET, NW, WASHINGTON DC 20008
Richard Straube	officer: CMO	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Christopher Schaber	director, officer: Chairman, CEO and President	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Jonathan L. Guarino	officer: Chief Financial Officer	100 WELLESLEY WAY, FREEHOLD NJ 07728
Oreola Donini	officer: CSO	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Robert J. Rubin	director	7901 SPRINGER ROAD, BETHESDA MD 20817
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Diane L. Parks	director	29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Mark E. Pearson	director, 10 percent owner	3031 TISCH WAY, SUITE 505, SAN JOSE CA 95128
Preta Martina Cavazza	other: Former 10% Owner	VIA SUDAFRICA 20, ROME L6 00144
Enrico Cavazza	other: Former 10% Owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza	other: Former 10% Owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Francesca Cavazza	other: Former 10% Owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Spa Essetifin	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144